Cargando…
Patient reported outcome measures in Waldenström macroglobulinaemia: A real‐world data analysis from the WMUK Rory Morrison Registry
Waldenström macroglobulinaemia (WM) is an incurable chronic B‐cell malignancy, but highly responsive to treatment. Treatments include fixed‐duration chemotherapy and continuous oral chemoimmunotherapy. In this expanding field, it is important to have reliable information on the impact of the various...
Autores principales: | Khwaja, Jahanzaib, Uppal, Encarl, Bristogiannis, Sotirios, McCarthy, Helen, Kothari, Jaimal, Rismani, Ali, Scorer, Harriet, Nicholson, Jane, El‐Sharkawi, Dima, D'Sa, Shirley, Kyriakou, Charalampia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928784/ https://www.ncbi.nlm.nih.gov/pubmed/36819170 http://dx.doi.org/10.1002/jha2.640 |
Ejemplares similares
-
P1149: THE EVOLVING STATE OF PLAY IN 1000 PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINAEMIA IN THE UNITED KINGDOM (UK): A REAL-WORLD DATA ANALYSIS FROM THE WMUK RORY MORRISON REGISTRY PROJECT
por: Uppal, E., et al.
Publicado: (2022) -
Systematic literature review of quality‐of‐life questionnaires in Waldenström macroglobulinaemia—need for a disease‐specific tool
por: Bristogiannis, Sotirios, et al.
Publicado: (2023) -
Bortezomib‐based therapy is effective and well tolerated in frontline and multiply pre‐treated Waldenström macroglobulinaemia including BTKi failures: A real‐world analysis
por: Khwaja, Jahanzaib, et al.
Publicado: (2022) -
P1150: REAL WORLD DATA ON BORTEZOMIB-BASED THERAPY IN WALDENSTRÖM’S MACROGLOBULINAEMIA: EFFECTIVE EVEN IN MULTIPLY TREATED PATIENTS INCLUDING PRIOR BTK-INHIBITORS
por: Uppal, E., et al.
Publicado: (2022) -
Cutaneous Involvement in Waldenström’s Macroglobulinaemia
por: STIEN, Sarah, et al.
Publicado: (2020)